Compare NTST & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | NUVB |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2020 | 2020 |
| Metric | NTST | NUVB |
|---|---|---|
| Price | $17.88 | $4.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 13 |
| Target Price | ★ $21.20 | $13.00 |
| AVG Volume (30 Days) | 1.7M | ★ 5.2M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | ★ 150.00 | 71.56 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $195,006,000.00 | $62,902,000.00 |
| Revenue This Year | $30.05 | $209.36 |
| Revenue Next Year | $21.08 | $41.60 |
| P/E Ratio | $87.28 | ★ N/A |
| Revenue Growth | 19.79 | ★ 698.96 |
| 52 Week Low | $16.18 | $3.92 |
| 52 Week High | $22.47 | $9.75 |
| Indicator | NTST | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 40.19 |
| Support Level | $17.89 | $4.10 |
| Resistance Level | $20.99 | $5.11 |
| Average True Range (ATR) | 0.46 | 0.23 |
| MACD | 0.16 | 0.06 |
| Stochastic Oscillator | 96.41 | 52.03 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.